Capstan is preparing for first-in-human trials in early 2025 and has raised $31.4 million in a previous financing round.
Company Description
Capstan Medical is developing heart valve implants with a robotic delivery platform, focusing on minimally invasive solutions for mitral and tricuspid valve regurgitation.